.jpeg)
{{ variable.name }}
Zoledronic Acid (Zoledronic Acid) instruction manual
Common name: Zoledronic acid
Trade name: Ireinin
Full names: Zoledronic acid, Ireinin, zoledronic acid for injection, 1-hydroxy-2-(imidazol-1-yl)-ethylene-1,1-bisphosphate, Zoledronic Acid,
Indications:
Pain caused by osteolytic bone metastasis of malignant tumors.
Usage and dosage:
Intravenous drip. For adults, 4 mg each time should be diluted with 100 ml of 0.9% sodium chloride injection or 5% glucose injection and then infused intravenously. The infusion time should be no less than 15 minutes. Administer every 3-4 weeks or as directed by your doctor.
Contraindications:
Contraindicated for patients allergic to this product or other bisphosphonates
Not recommended for patients with severe renal insufficiency
Contraindicated for pregnant and lactating women
Precautions:
When using this product for the first time, the levels of serum calcium, phosphorus, magnesium and serum creatinine should be closely monitored. If the levels of calcium, phosphorus and magnesium in the serum appear, If the dose is too low, necessary supplementary treatment should be given;
Patients with malignant hypercalcemia should fully rehydrate before giving this product. Diuretics can only be used after sufficient rehydration when combined with this product. Caution should be used when this product is combined with nephrotoxic drugs;
If renal function worsens when receiving this product, the drug should be discontinued until the renal function returns to baseline;
Asthma patients who are allergic to aspirin should use this product with caution.
It is not clear whether this product will be secreted into breast milk. Because this product can combine with bones for a long time, pregnant and lactating women are prohibited from using this product.
The safety and effectiveness of this product in children has not been established, and its use is not recommended for the time being.
Medication for the elderly is the same as for adults. However, elderly patients often have lower renal function and their renal function should be closely monitored during administration.
Drug interactions: Caution should be exercised when using this product in combination with aminoglycosides, as aminoglycosides have a synergistic effect in lowering blood calcium and may prolong the duration of hypocalcemia; when used in combination with diuretics, the risk of hypocalcemia may be increased, and when used in combination with thalidomide, the risk of abnormal renal function in patients with multiple myeloma may be increased. It's not clear yet.
Storage:
Save below 30℃
Mechanism of action:
The main pharmacological effect of zoledronic acid is to inhibit bone resorption. Its mechanism of action is not completely clear and may be related to multiple effects. Zoledronic acid can inhibit osteoclast activity and induce osteoclast apoptosis in vitro. It can also block the resorption of mineralized bone and cartilage by osteoclasts by binding to bone. Zoledronic acid can also inhibit the increase in osteoclast activity and bone calcium release induced by a variety of stimulating factors produced by tumors.